• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr. Adil Daud Discusses Zelboraf and Yervoy for the Treatment of Metastatic Melanoma

Article

Dr. Adil Daud, Clinical Professor of Medicine and Co-Director of the Melanoma Program, UCSF, discusses cost and the payer/provider relationship around metastatic melanoma medications.

vemurafenib (Brand name:

Dr. Daud discusses the use of Zelboraf) and ipilimumab (Brand name: Yervoy), the FDA-approved medications used in the treatment of metastatic melanoma. The medications are expensive, but Dr. Daud shares there have been little issue covering these specific drugs since they are so effective. Dr. Daud hopes that these are only the first class of this drug pathway extending life expectancy, as he hopes they can eventually bring metastatic melanoma to a chronic disease state and not a death sentence.

Related Videos
Refat Rasul Srejon, MPH
Screenshot of an interview with Nicolas Girard, MD, PhD
Byoung Chul Cho, MD, PhD
Beth Stein, MD, and Ratna Kiran Bhavaraju-Sanka, MD
Efren Flores, MD
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.